TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RVNC
SAN DIEGO--(BUSINESS WIRE)--#RVNCstock--Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (“Class Period”) have until this upcoming Tuesday, February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance…
Read More...
